We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will UnitedHealth (UNH) Q1 Earnings Buoy on Revenue Growth?
Read MoreHide Full Article
We expect higher revenues at UnitedHealthcare and Optum segments to drive UnitedHealth Group Inc.’s (UNH - Free Report) first-quarter results scheduled to release on Apr 17, 2018. Results should benefit from a reduction in corporate tax, partly offset by decline in premium revenues due to minimum loss ratio and lower net health insurance fee recapture effects.
Alongside, the company is expected to incur additional investment and operating costs in order to accelerate existing initiatives and artificial intelligence, data analytics, individual health record custodianship, digital health, net promoter score improvements and health related initiatives in local communities. These accelerated investments will lead to $200 million to $300 million in incremental operating expense for 2018. A part of these spend will be borne by the company in the first quarter, which might increase operating expense.
Factors to Influence Q1 Results
Revenue Growth at UnitedHealthcare: This segment is expected to witness an increased revenue led by growth in the number of individuals served across its business lines and price increases for underlying medical cost trends, which might be partially offset by a reduction in the number of people served in ACA-compliant individual products. The Zacks Consensus Estimate for the segment’s revenues is $44.7 billion, up 11.5% year over year.
Higher Membership: We expect membership enrollment growth at the company. This should be led by broad-based growth across group sizes and regions in the commercial group market on the back of gains in services to small groups, which should drive membership in risk-based benefit plans. Fee-based commercial group business might be under pressure due to the non-renewal of one public sector customer. We expect to see higher Medicare advantage membership from growth in individual and employer-sponsored group Medicare Advantage plans. Strong customer retention and new sales should cause higher membership in Medicaid.
Higher Contribution from Optum: Results should also show an increase in revenues from its health services’ segment Optum, driven by higher contribution from sub-segments OptumHealth, OptumInsight and OptumRx. Revenues and earnings from operations increased at OptumHealth primarily due to organic and acquisition-related growth in care delivery. OptumInsight should see growth in revenue management services and business process services, whereas OptumRx should see an upside from client and consumer growth. The Zacks Consensus Estimate for revenues from the segment is $23.6 billion, up 11.3% year over year.
The bottom line should further get a cushion from the shares bought back in the first quarter.
UnitedHealth Group Incorporated Price and EPS Surprise
Our proven model does not conclusively show that UnitedHealth is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: UnitedHealth has an Earning ESP of -1.05%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Though UnitedHealth carries a Zacks Rank #2 (Buy), its negative ESP makes our surprise prediction difficult.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some companies that you may consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
Molina Healthcare, Inc. (MOH - Free Report) has an Earnings ESP of +14.57% and a Zacks Rank #3 (Hold). The company is expected to report first-quarter earnings results on Apr 30.
Magellan Health, Inc. has an Earnings ESP of +2.54% and a Zacks Rank #2. The company is expected to report first-quarter earnings results on Apr 26.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Will UnitedHealth (UNH) Q1 Earnings Buoy on Revenue Growth?
We expect higher revenues at UnitedHealthcare and Optum segments to drive UnitedHealth Group Inc.’s (UNH - Free Report) first-quarter results scheduled to release on Apr 17, 2018. Results should benefit from a reduction in corporate tax, partly offset by decline in premium revenues due to minimum loss ratio and lower net health insurance fee recapture effects.
Alongside, the company is expected to incur additional investment and operating costs in order to accelerate existing initiatives and artificial intelligence, data analytics, individual health record custodianship, digital health, net promoter score improvements and health related initiatives in local communities. These accelerated investments will lead to $200 million to $300 million in incremental operating expense for 2018. A part of these spend will be borne by the company in the first quarter, which might increase operating expense.
Factors to Influence Q1 Results
Revenue Growth at UnitedHealthcare: This segment is expected to witness an increased revenue led by growth in the number of individuals served across its business lines and price increases for underlying medical cost trends, which might be partially offset by a reduction in the number of people served in ACA-compliant individual products. The Zacks Consensus Estimate for the segment’s revenues is $44.7 billion, up 11.5% year over year.
Higher Membership: We expect membership enrollment growth at the company. This should be led by broad-based growth across group sizes and regions in the commercial group market on the back of gains in services to small groups, which should drive membership in risk-based benefit plans. Fee-based commercial group business might be under pressure due to the non-renewal of one public sector customer. We expect to see higher Medicare advantage membership from growth in individual and employer-sponsored group Medicare Advantage plans. Strong customer retention and new sales should cause higher membership in Medicaid.
Higher Contribution from Optum: Results should also show an increase in revenues from its health services’ segment Optum, driven by higher contribution from sub-segments OptumHealth, OptumInsight and OptumRx. Revenues and earnings from operations increased at OptumHealth primarily due to organic and acquisition-related growth in care delivery. OptumInsight should see growth in revenue management services and business process services, whereas OptumRx should see an upside from client and consumer growth. The Zacks Consensus Estimate for revenues from the segment is $23.6 billion, up 11.3% year over year.
The bottom line should further get a cushion from the shares bought back in the first quarter.
UnitedHealth Group Incorporated Price and EPS Surprise
UnitedHealth Group Incorporated Price and EPS Surprise | UnitedHealth Group Incorporated Quote
Here is what our quantitative model predicts
Our proven model does not conclusively show that UnitedHealth is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: UnitedHealth has an Earning ESP of -1.05%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Though UnitedHealth carries a Zacks Rank #2 (Buy), its negative ESP makes our surprise prediction difficult.
We caution against Sell-rated stocks (Zacks Rank #4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are some companies that you may consider as our model shows that these have the right combination of elements to post an earnings beat this quarter:
Humana Inc. (HUM - Free Report) is expected to report first-quarter 2018 earnings results on May 2. The company has an Earnings ESP of +0.41% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Molina Healthcare, Inc. (MOH - Free Report) has an Earnings ESP of +14.57% and a Zacks Rank #3 (Hold). The company is expected to report first-quarter earnings results on Apr 30.
Magellan Health, Inc. has an Earnings ESP of +2.54% and a Zacks Rank #2. The company is expected to report first-quarter earnings results on Apr 26.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>